Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06626230
PHASE1

Safety of Anal Curcumin

Sponsor: Lisa Flowers

View on ClinicalTrials.gov

Summary

The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.

Official title: An Incremental Dose Escalation Trial of Safety and Tolerability of Curcumin

Key Details

Gender

All

Age Range

30 Years - Any

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2025-03-17

Completion Date

2026-01

Last Updated

2025-04-23

Healthy Volunteers

Yes

Interventions

DRUG

Curcuminoid Capsules

500 mg curcuminoids from C3 Complex capsule. Curcuma longa (Turmeric), a constituent of the spice turmeric, is considered a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits Study participants will be instructed to insert the curcumin capsules gelatin intra-anally every day for a 14-day treatment period. Escalating doses

Locations (2)

Grady Memorial Hospital

Atlanta, Georgia, United States

Grady Hospital - Ponce De Leon Clinic

Atlanta, Georgia, United States